Selective and specific I f inhibition with ivabradine: New perspectives for the treatment of cardiovascular disease

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 8, 2011, Pages 959-973

  Ferrari, Roberto ^a   Ceconi, Claudio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

angina; coronary artery disease; heart failure; heart rate; heart rate reducing agents; If inhibition; ivabradine; sinoatrial node

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; CLARITHROMYCIN; DILTIAZEM; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; IVABRADINE; KETOCONAZOLE; NELFINAVIR; NITRATE; PLACEBO; PROPRANOLOL; PROTON PUMP INHIBITOR; RITONAVIR; SILDENAFIL; TELITHROMYCIN; VERAPAMIL;

ANGINA PECTORIS; AREA UNDER THE CURVE; ATHEROSCLEROTIC PLAQUE; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CLINICAL RESEARCH; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HEART RATE; HEART VENTRICLE REMODELING; HUMAN; HYPERCHOLESTEROLEMIA; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; NONHUMAN; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STABLE ANGINA PECTORIS; SYSTOLIC DYSFUNCTION; VASOCONSTRICTION;

ANIMALS; BENZAZEPINES; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DEPRESSION, CHEMICAL; DRUG INTERACTIONS; HEART RATE; HUMANS; MYOCARDIAL CONTRACTION; VENTRICULAR FUNCTION, LEFT;

EID: 80052456261     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.99     Document Type: Review

References (59)

1. Jouven X, Empana JP, Buyck JF et al. Resting heart rate and its changes over years as a risk factor for mortality in the general population: the Paris Prospective Study I. Eur. Heart J. 27, 333 (2007).
2. Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur. Heart J. 18, 1404-1410 (1997).
3. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am. Heart J. 125, 1148-1154 (1993).
4. Hjalmarson A, Gilpin EA, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infarction. Am. J. Cardiol. 65, 547-553 (1990).
5. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372, 817-821 (2008).
6. Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International Verapamil-SR/Trandolapril Study (INVEST). Eur. Heart J. 29, 1327-1334 (2008).
7. Bohm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376, 886-894 (2010).
8. Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103, 1428-1433 (2001).
9. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur. Heart J. 28, 3012-3019 (2007).
10. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving b-blockers. Am. J. Cardiol. 101, 865-869 (2008).
11. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: b-blocker dose, heart rate reduction, and death in patients with heart failure. Ann. Intern. Med. 150, 784-794 (2009).
12. Guth BD, Heusch G, Seitelberger R, Ross J Jr. Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis. Circulation 75, 661-669 (1987).
13. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br. J. Pharmacol. 153, 1589-1601 (2008).
14. Schulz R, Rose J, Skyschally A, Heusch G. Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the β-blocker atenolol. J. Cardiovasc. Pharmacol. 25, 216-228 (1995).
15. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature 280, 235-236 (1979).
16. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu. Rev. Physiol. 55, 455-472 (1993).
17. Vilaine JP. The discovery of the selective If current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol. Res. 53, 424-434 (2006).
18. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br. J. Pharmacol. 118, 1051-1057 (1996).
19. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol. Res. 53, 399-406 (2006).
20. Borer JS, Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective If current inhibitor. Am. J. Ther. 15, 461-473 (2008).
21. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4, 83-89 (2003).
22. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J. Pharmacol. Exp. Ther. 275, 659-666 (1995).
23. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49 Br. J. Pharmacol. 112, 37-42 (1994).
24. Vilaine JP, Bidouard JP, Lesage L, Reure H, Peglion JL. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J. Cardiovasc. Pharmacol. 42, 688-696 (2003).
25. Colin P, Ghaleh B, Monnet X et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am. J. Physiol. Heart Circ. Physiol. 284, H676-H682 (2003).
26. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J. Pharmacol. Exp. Ther. 308, 236-240 (2004).
27. Heusch G. a-adrenergic mechanisms in myocardial ischemia. Circulation 81, 1-13 (1990).
28. Heusch G, Baumgart D, Camici P et al. a-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 101, 689-694 (2000).
29. Ceconi C, Cargnoni A, Francolini G, Parinello G, Ferrari R. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc. Res. 84, 72-82 (2009).
30. Heusch G, Skyschally A, Gres P, Van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur. Heart J. 29, 2265-2275 (2008).
31. Heusch G. Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br. J. Pharmacol. 155, 970-971 (2008).
32. Custodis F, Schirmer SH, Baumhakel M, Heusch G, Bohm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J. Am. Coll. Cardiol. 56, 1973-1983 (2010).
33. Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br. J. Pharmacol. 154, 749-757 (2008).
34. Custodis F, Baumhakel M, Schlimmer N et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117, 2377-2387 (2008).
35. Walcher T, Bernhardt P, Vasic D et al. Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration. Mediators Inflamm. 2010, 751313 (2010).
36. Heusch G. Heart rate and heart failure. Not a simple relationship. Circ. J. 75, 229-236 (2011).
37. Ceconi C, Comini L, Suffredini S et al. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am. J. Physiol. Heart Circ. Physiol. 300, H366-H373 (2010).
38. Mulder P, Barbier S, Chagraoui A et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109, 1674-1679 (2004).
39. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372, 807-816 (2008).
40. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 376, 875-885 (2010).
41. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107, 817-823 (2003).
42. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 67, 393-405 (2007).
43. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur. Heart J. 26, 2529-2536 (2005).
44. Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving b-blocker therapy: a 4 month, randomized, placebo-controlled trial. Eur. Heart J. 30, 540-548 (2009).
45. Lopez-Bescos L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology 108, 387-396 (2007).
46. Tendera M, Borer J, Tardif J. Efficacy of If inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology 114, 116-125 (2009).
47. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur. Heart J. 17, 96-103 (1996).
48. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron. Artery Dis. 13, 427-436 (2002).
49. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J. 30, 2337-2345 (2009).
50. Heusch G. A BEAUTIFUL lesson - ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur. Heart J. 30, 2300-2301 (2009).
51. Koster R, Kaehler J, Meinertz T. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am. Heart J. 158, e51-e57 (2009).
52. Koester R, Kaehler J, Meinertz T. Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin. Res. Cardiol. 100(2), 121-128 (2010).
53. Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T. Ivabradine in combination with b-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin. Res. Cardiol. 99, 665-672 (2010).
54. Savelieva I, Camm AJ. If inhibition with ivabradine: Electrophysiological effects and safety. Drug Saf. 31, 95-107 (2008).
55. Tendera M, Talajic M, Robertson M et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am. J. Cardiol. 107, 805-811 (2011).
56. Daly C, Clemens F, Lopez-Sendon J et al. Indequate control of heart rate in patients with stable angina: results from the European Heart Survey. Postgrad. Med. J. 86(1014), 212-217 (2010).
57. Bax J, Achenbach S, Cademartiri F, Garot J, Tendera M, Zamorano J. A randomized double blind trial on the efficacy and safety of a single intravenous bolus of ivabradine versus placebo for heart rate control during coronary CT angiography. Eur. Heart J. 31(Suppl.), 151 (2010) (Abstract 950).
58. Steg PG, Lopez-Sendon JL. A pilot randomized trial of intravenous ivabradine vs placebo on top of usual care following percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Circulation 122, A14196 (2010).
59. Turner R.C., Millns H.,Neil H.A.W.,Stratton I.M.,Manley S.E.,Matthews D.R.,Holman R.R., Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23), British Medical Journal 1998, 316, 7134, 823-828.